Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

March 31, 2025
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

MetaVia Inc. (MTVA-NASDAQ)

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

Based on our probability adjusted DCF model that takes into account potential future revenues from DA-1241 and DA-1726, MTVA is valued at $23.00/share. This model is highly dependent upon continued clinical success of the company's assets and will be adjusted accordingly based upon future clinical results.

Current Price (03/31/25)	$1.58
Valuation	**$23.00**

OUTLOOK

On March 20, 2025, MetaVia Inc. (MTVA) announced financial results for 2024 and provided a business update. We anticipate topline results from the multiple ascending dose (MAD) Part 2 of the Phase 1 trial of DA-1726 to be reported in April 2025. DA-1726 is the company's novel dual oxyntomodulin analog that functions as a dual glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist. While market conditions and sentiment continue to trend negative for the biotech sector as a whole, the one exception appears to be the obesity space. Just in the past month three deals were announced, indicating that Big Pharma continues to be interested in acquiring differentiated obesity therapies.

SUMMARY DATA

52-Week High	**$5.00**
52-Week Low	**$1.45**
One-Year Return (%)	**-61.49**
Beta	**0.27**
Average Daily Volume (sh)	**22,806**
Shares Outstanding (mil)	**9**
Market Capitalization ($mil)	**$14**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**1**
Insider Ownership (%)	**1**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2025 Estimate	**N/A**
P/E using 2026 Estimate	**N/A**

Risk Level	**High**
Type of Stock	**Small-Value**
Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	0 A	0 A	0 A	0 A	0 A
2025	0 E	0 E	0 E	0 E	0 E
2026					0 E
2027					0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	-$1.32 A	-$1.85 A	-$0.55 A	-$0.50 A	-$3.56 A
2025	-$0.57 E	-$0.62 E	-$0.52 E	-$0.51 E	-$2.26 E
2026					-$1.65 E
2027					-$1.53 E

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Business Update

Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726

MetaVia Inc. (MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to receive DA-1726 or placebo. The results showed that DA-1726 was safe, well tolerated, and had linear pharmacokinetics (PK). In regards to safety, only five subjects in the DA-1726 group reported adverse events (AEs) compared to three subjects in the placebo group. Due to the strong safety profile, at least one additional dosing cohort is being added to evaluate the maximum tolerated dose.

The multiple ascending dose (MAD) Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each participant will receive four weekly administrations of DA-1726 or placebo. We anticipate topline results from Part 2 of the study in April 2025.

The company continues planning for Part 3 of the trial, which we anticipate initiating in the fourth quarter of 2025, with an interim data readout in mid-2026 and topline results being reported in the second half of 2026. The following slide provides an overview of Part 3 of the trial, which will evaluate early proof of concept and maximum titratable dose of DA-1726.



Source: MetaVia Inc.

M&A Activity Continues in Obesity Space

While the biotech sector as a whole has been experiencing a relative downturn, there continues to be robust partnering activities for obesity therapies, as exemplified by the following deals announced in just the past month:

- On March 3, 2025, AbbVie (ABBV) announced a licensing deal with Gubra A/S to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under terms of the deal, Gubra will receive a $350 million upfront cash payment and be eligible for up to $1.875 billion in development, commercial, and sales milestone payments with tiered royalties on global net sales. This marks AbbVie's entrance into the obesity field.

- On March 12, 2025, Roche announced a collaboration and licensing agreement with Zealand Pharma under which the companies will co-develop and co-commercialize petrelinitide, a long-acting amylin analog, as a standalone therapy and as a fixed-dose combination with Roche's lead asset CT-388. Under terms of the agreement, Zealand Pharma will receive upfront cash payments of $1.65 billion ($1.4 billion at close and $250 million over the first two anniversaries of the collaboration), be eligible for development milestones of $1.2 billion, and sales-based milestones of $2.4 billion. Profits and losses from the sale of petrelintide and petrelintide/CT-388 will be shared 50/50 in the U.S. and Europe and Zealand Pharma is eligible to receive tiered double-digit royalties up to the high teens on net sales in the rest of the world.

- On March 24, 2025, Novo Nordisk announced an exclusive licensing agreement with The United Bio-Technology Co., Ltd. for UTB251, a triple agonist of the receptors for GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon, which is early-stage development for the treatment of obesity, type 2 diabetes, and other diseases. Under terms of the agreement, United Biotechnology will receive an upfront payment of $200 million and be eligible for potential milestone payments of up to $1.8 billion along with tiered royalties on net sales outside of China, Hong Kong, Macau, and Taiwan.

We view these deals as evidence that Big Pharma companies continue to be actively looking for differentiated obesity treatments and those companies are willing to pay substantial amounts to enter into development partnerships for those assets.

Financial Update

On March 20, 2025, MetaVia announced financial results for fiscal year 2024. As expected, the company did not report any revenues in the year ending December 31, 2024. R&D expenses in 2024 were approximately $21.6 million compared to approximately $9.2 million in 2023. The increase was primarily attributed to increased drug manufacturing costs, non-clinical and pre-clinical services, clinical trials, and employee compensation. G&A expenses in 2024 were approximately $7.3 million compared to approximately $6.7 million in 2023. The increase was primarily attributable to higher employee compensation and benefits partially offset by lower consulting expenditures and legal fees.

As of December 31, 2024, MetaVia had approximately $16.0 million in cash and cash equivalents. We estimate that this is sufficient to fund operations into the third quarter of 2025. As of March 17, 2025, MetaVia had approximately 8.7 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 23.1 million.

Conclusion

We are looking forward to the results from Part 2 of the Phase 1 trial, which we anticipate in April 2025. While the results will be primarily focused on safety and tolerability, given the four weeks of dosing the results could offer an early read on clinical efficacy. Looking ahead, Part 3 of the Phase 1 trial will initiate in the fourth quarter of 2025, with an interim read-out planned for mid-2026 and topline results expected by the end of 2026. Following the release of positive Phase 2a results for DA-1241 in MASH in December 2024, the company is planning to conduct an 'end-of-Phase 2' meeting with the FDA in the first half of 2025 and the full data set from the Phase 2a study will be presented at a major medical meeting later this year. As we await the results from Part 2 of the Phase 1 trial of DA-1726 our valuation remains at $23.00 per share.

PROJECTED FINANCIALS

MetaVia Inc.	2024 A	Q1 E	Q2 E	Q3 E	Q4 E	2025 E	2026 E	2027 E
DA-1241	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
DA-1726	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Other Income	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**
Cost of revenues	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Research & Development	$21.6	$4.3	$4.6	$4.8	$5.0	$18.7	$20.0	$22.0
General & Administrative	$7.3	$1.7	$1.8	$2.0	$2.1	$7.6	$8.0	$8.5
Other (Income) Expense	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Operating Income	($28.8)	($6.0)	($6.4)	($6.8)	($7.1)	($26.3)	($28.0)	($30.5)
Operating Margin	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*	*#DIV/0!*
Non-Operating Expenses (Net)	$1.2	$0.2	$0.0	$0.6	$0.0	$0.0	$0.0	$0.0
Pre-Tax Income	($27.6)	($5.8)	($6.4)	($6.2)	($7.1)	($26.3)	($28.0)	($30.5)
Income Taxes	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	**($27.6)**	**($5.8)**	**($6.4)**	**($6.2)**	**($7.1)**	**($26.3)**	**($28.0)**	**($30.5)**
Net Margin	-	-	-	-	-	-	-	-
Reported EPS	**($3.56)**	**($0.57)**	**($0.62)**	**($0.52)**	**($0.51)**	**($2.26)**	**($1.65)**	**($1.53)**
YOY Growth	-	-	-	-	-	-	-	-
Basic and Diluted Shares Outstanding	7.8	10.3	10.3	12.0	14.0	11.7	17.0	20.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



Source: Zacks SCR

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.